A recent study indicates that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop traditional diet and exercise plans.
Findings released in a major medical journal points out that while overweight individuals can lose substantial amounts of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing these medications should be aware of the potential of quick weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of regain implies a return to original weight in about one and a half years.
Weighing Treatments
The study, which reviewed 37 of trials involving thousands of participants, contrasted the results of the injectable medications with other pills.
Scientists emphasize that individuals who shed pounds through diet and exercise usually experience a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Nutrition scientists propose the mode of action of the jabs is key to understanding the accelerated weight return.
These medications mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication means appetite is uncontrolled, making overeating much more probable."
A Lifelong Condition?
Medical guidelines advise the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals argue that, considering the high risk of weight regain, the therapy might need to be life-long.
This view is reinforced by pharmaceutical companies, who note that the results "emphasize the chronic character of excess weight," akin to managing conditions like high blood pressure.
Patient Testimonies
Users who have discontinued the medication explain a intense return of appetite.
"It felt as if a trigger activating and I was suddenly starving," described an individual.
This challenge is worsened if patients have not developed sustainable lifestyle or habit changes during therapy.
Growing Use
Recent estimates suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone solution and long-term success likely depends on combined behavioural support.
